标题/作者	年份
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ... New England Journal of Medicine 378 (22), 2093-2104	2018
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229	2018
Fundamental mechanisms of immune checkpoint blockade therapy SC Wei, CR Duffy, JP Allison Cancer discovery 8 (9), 1069-1086	2018
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy JJ Havel, D Chowell, TA Chan Nature Reviews Cancer 19 (3), 133-150	2019
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56	2019
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365	2020
Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167	2019
Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4	2018
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach C Luchini, F Bibeau, MJL Ligtenberg, N Singh, A Nottegar, T Bosse, ... Annals of Oncology 30 (8), 1232-1243	2019
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors AA Davis, VG Patel Journal for immunotherapy of cancer 7 (1), 1-8	2019
MHC-II neoantigens shape tumour immunity and response to immunotherapy E Alspach, DM Lussier, AP Miceli, I Kizhvatov, M DuPage, AM Luoma, ... Nature 574 (7780), 696-701	2019
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy F Skoulidis, JV Heymach Nature Reviews Cancer 19 (9), 495-509	2019
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672	2021
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992	2019
Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126	2019
Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non–small cell lung cancer with use of a next-generation sequencing cancer gene panel Z Wang, J Duan, S Cai, M Han, H Dong, J Zhao, B Zhu, S Wang, M Zhuo, ... JAMA oncology 5 (5), 696-702	2019
Brain immunology and immunotherapy in brain tumours JH Sampson, MD Gunn, PE Fecci, DM Ashley Nature Reviews Cancer 20 (1), 12-25	2020
The challenges of tumor mutational burden as an immunotherapy biomarker DL Jardim, A Goodman, D de Melo Gagliato, R Kurzrock Cancer cell 39 (2), 154-173	2021
Genomic correlates of response to immune checkpoint blockade TE Keenan, KP Burke, EM Van Allen Nature medicine 25 (3), 389-402	2019
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6)	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。